Stock listing

NASDAQ:SMMT Summit Therapeutics Inc. Stock

Home listing (NASDAQ) of Summit Therapeutics Inc.

Follow Summit Therapeutics Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SMMT

$15.69 USD +1.06 (+7.2%)

Delayed at least 15 minutes · 3:45 PM EDT, Oct 19, 2026

Past year -27.0% · daily closes, Oct 20, 2025 – Oct 16, 2026, adjusted for splits
Day range so far
$14.83 – $15.77 USDDelayed at least 15 minutes · 3:45 PM EDT, Oct 19, 2026
Volume
4.36M sharesDelayed at least 15 minutes · 3:45 PM EDT, Oct 19, 2026
Market value
$12.51B USDDelayed at least 15 minutes · 3:45 PM EDT, Oct 19, 2026 · price × 797.7M shares outstanding
52-week range
$12.07 – $29.23 USDLowest and highest trades, Oct 20, 2025 – Oct 19, 2026
Summit Therapeutics Inc. logo
Ticker
NASDAQ:SMMT
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Summit Therapeutics (NASDAQ:SMMT) Q2 2026 Earnings Call

    Thu, Jul 23, 2026 · 4:30 PM ET

    Watch Transcript

  • Summit Therapeutics (NASDAQ:SMMT) Q4 2025 Earnings Call

    Mon, Feb 23, 2026 · 4:30 PM ET

    Watch Transcript

  • Summit Therapeutics (NASDAQ:SMMT) Q3 2025 Earnings Call

    Mon, Oct 20, 2025 · 8:00 AM ET

    Watch Transcript

Latest news

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma

Oct 19, 2026

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Oct 5, 2026

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

Oct 2, 2026

Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types

Oct 2, 2026

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics

Sep 28, 2026

HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026

Sep 22, 2026

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

Sep 15, 2026

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China

Sep 13, 2026

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Aug 25, 2026

Summit Therapeutics - Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer

Aug 13, 2026

All Summit Therapeutics Inc. news

Financings

  • Strategic investment of convertible preferred stock

    Oct 5, 2026

    Closed: US$2B raised

    Buyers: AstraZeneca (approximately 108,955 shares of convertible preferred stock for $2.0 billion)

    Use of proceeds: Accelerated development of ivonescimab across solid tumor settings, including combinations with antibody drug conjugates

    Announced Sep 28, 2026 · Closed Oct 5, 2026

Read by 6ix AI from the company's releases

Decks

Summit Therapeutics Inc. on 6ix

News releases
34 in the last 12 months · 157 in all · newest Oct 19, 2026 · oldest 2019
Calls
11 calls with a replay · 11 with a transcript · latest Jul 23, 2026
Decks
31 decks · latest Jul 23, 2026

Where Summit Therapeutics Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SMMT · Home listing · This pageNASDAQUnited StatesUSD
BMV:SMMTBMVMexicoMXN
BOATS:SMMTBOATSUnited StatesUSD
BIVA:SMMTBIVAMexicoMXN

Log in to ask 6ix AI your own questions about Summit Therapeutics Inc.